Ozempic for Heart Disease — The New Research - Who Gets the Drug and Who Gets Left Behind

Impossible d'ajouter des articles

Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.

Veuillez réessayer plus tard

Échec de l’élimination de la liste d'envies.

Veuillez réessayer plus tard

Impossible de suivre le podcast

Impossible de ne plus suivre le podcast

Ozempic for Heart Disease — The New Research - Who Gets the Drug and Who Gets Left Behind

Écouter gratuitement

Voir les détails

À propos de ce contenu audio

Julia Cartwright examines who can actually access semaglutide's life-saving heart benefits after FDA approval. She explores the SELECT trial's 20% cardiac event reduction, the 6.6 million eligible Americans, insurance barriers, cost challenges, and the stark gap between proven science and real-world accessibility for cardiovascular disease patients.

Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

This content was created in partnership and with the help of Artificial Intelligence AI

Aucun commentaire pour le moment